DK170164B1 - 3,3-Heterocyclisk disubstituerede indoliner samt N-oxider og farmaceutisk acceptable syreadditionssalte deraf, fremgangsmåde til deres fremstilling og farmaceutisk præparat indeholdende dem - Google Patents

3,3-Heterocyclisk disubstituerede indoliner samt N-oxider og farmaceutisk acceptable syreadditionssalte deraf, fremgangsmåde til deres fremstilling og farmaceutisk præparat indeholdende dem Download PDF

Info

Publication number
DK170164B1
DK170164B1 DK182087A DK182087A DK170164B1 DK 170164 B1 DK170164 B1 DK 170164B1 DK 182087 A DK182087 A DK 182087A DK 182087 A DK182087 A DK 182087A DK 170164 B1 DK170164 B1 DK 170164B1
Authority
DK
Denmark
Prior art keywords
acid addition
pharmaceutically acceptable
bis
acceptable acid
pyridylmethyl
Prior art date
Application number
DK182087A
Other languages
Danish (da)
English (en)
Other versions
DK182087D0 (da
DK182087A (da
Inventor
Melvyn John Myers
Victor Johannes Nickolson
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of DK182087D0 publication Critical patent/DK182087D0/da
Publication of DK182087A publication Critical patent/DK182087A/da
Application granted granted Critical
Publication of DK170164B1 publication Critical patent/DK170164B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK182087A 1986-04-10 1987-04-09 3,3-Heterocyclisk disubstituerede indoliner samt N-oxider og farmaceutisk acceptable syreadditionssalte deraf, fremgangsmåde til deres fremstilling og farmaceutisk præparat indeholdende dem DK170164B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85001586A 1986-04-10 1986-04-10
US85001586 1986-04-10
US94495387 1987-01-05
US06/944,953 US4760083A (en) 1986-04-10 1987-01-05 3,3-disubstituted indolines

Publications (3)

Publication Number Publication Date
DK182087D0 DK182087D0 (da) 1987-04-09
DK182087A DK182087A (da) 1987-10-11
DK170164B1 true DK170164B1 (da) 1995-06-06

Family

ID=27126891

Family Applications (1)

Application Number Title Priority Date Filing Date
DK182087A DK170164B1 (da) 1986-04-10 1987-04-09 3,3-Heterocyclisk disubstituerede indoliner samt N-oxider og farmaceutisk acceptable syreadditionssalte deraf, fremgangsmåde til deres fremstilling og farmaceutisk præparat indeholdende dem

Country Status (18)

Country Link
US (1) US4760083A (el)
EP (1) EP0241006B1 (el)
JP (1) JPH068293B2 (el)
KR (1) KR960007528B1 (el)
AT (1) ATE50572T1 (el)
AU (1) AU599370B2 (el)
CA (1) CA1301151C (el)
DE (1) DE3761768D1 (el)
DK (1) DK170164B1 (el)
ES (1) ES2054627T3 (el)
FI (1) FI89482C (el)
GR (1) GR3000359T3 (el)
HU (1) HU196792B (el)
IE (1) IE59680B1 (el)
MX (1) MX173308B (el)
NO (1) NO167661C (el)
NZ (1) NZ219928A (el)
PT (1) PT84651B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173489A (en) * 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
US5300642A (en) * 1986-04-10 1994-04-05 The Du Pont Merck Pharmaceutical Company α, α-disubstituted aromatics and heteroaromatics as cognition enhancers
US4791107A (en) * 1986-07-16 1988-12-13 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
US4806651A (en) * 1987-10-07 1989-02-21 E. I. Du Pont De Nemours And Company Process for preparing 3,3-disubstituted indolines
US4965066A (en) * 1989-06-06 1990-10-23 E. I. Du Pont De Nemours And Company Intranasal administration of 3,3-disubstituted indolines
US4914102A (en) * 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
US5260452A (en) * 1989-11-03 1993-11-09 Hoechst-Roussel Pharmaceuticals Inc. 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof
US5087628A (en) * 1990-01-12 1992-02-11 Du Pont Merck Pharmaceutical Company 4,4'-[9H-fluoren-9-ylidenebis (methylene)]bispyrimidine for treating neurological disorders
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278045A (en) * 1990-02-28 1994-01-11 Du Pont Merck Pharmaceutical Company Method and compositions to screen compounds for enhancement of the cholinergic, dopaminergic and serotonergic function
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
EP0623127B1 (en) * 1992-01-16 1997-04-02 The Du Pont Merck Pharmaceutical Company Novel neurotransmitter releasers useful for cognition enhancement
US5698559A (en) * 1992-01-16 1997-12-16 The Dupont Merck Pharmaceutical Company Disubstituted polycyclic systems as cognition enhancers
RU2051151C1 (ru) * 1992-01-16 1995-12-27 Дзе Дюпон Мерк Фармасьютикал Компани Азотсодержащие гетероциклические производные флуорена
AU4027693A (en) * 1992-04-16 1993-11-18 Du Pont Merck Pharmaceutical Company, The Substituted nitrogen containing spiro compounds for use in treating cognitive deficits
US5278162A (en) * 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
JPH08502293A (ja) * 1992-10-13 1996-03-12 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 認識疾患の治療に有用な３，３−ジ置換された三環式および四環式インドリン−２−オン
JP3419539B2 (ja) * 1993-02-17 2003-06-23 中外製薬株式会社 インドリン−２−オン誘導体
US5594001A (en) * 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
SK124695A3 (en) * 1993-04-08 1996-06-05 Du Pont Merck Pharma Disubstituted polycyclic compounds and their derivatives alone and for treatment, and pharmaceutical compositions on their base
US5308851A (en) * 1993-06-03 1994-05-03 The Du Pont Merck Pharmaceutical Company Bispyridyl-containing heterocycles useful for treating cognitive disorders
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
MX9605218A (es) * 1994-04-29 1997-10-31 Pfizer Amidas aciclicas y ciclicas novedosas como mejoradores de liberacion de neurotransmisores.
US5948781A (en) * 1997-05-27 1999-09-07 Pfizer Inc Adamantyl substituted oxindoles as pharmaceutical agents
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
KR100738136B1 (ko) 1999-07-30 2007-07-10 젠야쿠코교가부시키가이샤 아자인돌리지논 유도체 및 그것을 유효성분으로 하는뇌기능 개선제
FR2804115B1 (fr) * 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN108658834B (zh) * 2017-03-31 2021-03-23 烟台药物研究所 一种吲哚酮衍生物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1154976A (en) * 1967-02-21 1969-06-11 Pfizer Ltd N-Phenyl Indoline Derivatives
US3725403A (en) * 1970-10-20 1973-04-03 Squibb & Sons Inc Benzothiazine derivatives
ES426436A1 (es) * 1974-05-18 1976-07-01 Andreu Sa Dr Procedimiento para la obtencion de derivados de la 3,3-bis (4-hidroxifenil)-2-indolinona.
US4273860A (en) * 1977-12-28 1981-06-16 Eastman Kodak Company Inhibition of image formation utilizing cobalt(III) complexes
CU21107A3 (es) * 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
JPS55129284A (en) * 1979-03-27 1980-10-06 Shionogi & Co Ltd 3-(1-imipazolyl)indolin-2-one
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
US4476307A (en) * 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US4452990A (en) * 1982-11-15 1984-06-05 Warner-Lambert Company 1-Aroyl-5-oxo-2-pyrrolidinepropanoic acids and related esters
US4434169A (en) * 1983-01-03 1984-02-28 Warner-Lambert Company Pharmaceutical compositions and methods

Also Published As

Publication number Publication date
NO871492D0 (no) 1987-04-09
KR960007528B1 (ko) 1996-06-05
JPH068293B2 (ja) 1994-02-02
FI89482C (fi) 1993-10-11
NO871492L (no) 1987-10-12
KR870009996A (ko) 1987-11-30
EP0241006A3 (en) 1988-08-10
FI871556A0 (fi) 1987-04-09
DE3761768D1 (de) 1990-04-05
NZ219928A (en) 1989-08-29
AU7133487A (en) 1987-10-15
ATE50572T1 (de) 1990-03-15
DK182087D0 (da) 1987-04-09
HUT44028A (en) 1988-01-28
NO167661C (no) 1991-11-27
NO167661B (no) 1991-08-19
GR3000359T3 (en) 1991-06-07
EP0241006B1 (en) 1990-02-28
FI871556A (fi) 1987-10-11
MX173308B (es) 1994-02-15
PT84651A (en) 1987-05-01
FI89482B (fi) 1993-06-30
PT84651B (pt) 1989-12-29
US4760083A (en) 1988-07-26
IE59680B1 (en) 1994-03-23
IE870921L (en) 1987-10-10
JPS62277381A (ja) 1987-12-02
AU599370B2 (en) 1990-07-19
ES2054627T3 (es) 1994-08-16
EP0241006A2 (en) 1987-10-14
HU196792B (en) 1989-01-30
DK182087A (da) 1987-10-11
CA1301151C (en) 1992-05-19

Similar Documents

Publication Publication Date Title
DK170164B1 (da) 3,3-Heterocyclisk disubstituerede indoliner samt N-oxider og farmaceutisk acceptable syreadditionssalte deraf, fremgangsmåde til deres fremstilling og farmaceutisk præparat indeholdende dem
JP4718467B2 (ja) イソキノリノンカリウムチャネル阻害剤
FI93446C (fi) Menetelmä terapeuttisesti käyttökelpoisten , -disubstituoitujen aromaattisten ja heteroaromaattisten yhdisteiden valmistamiseksi
KR20100072266A (ko) 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
PT1765795E (pt) Derivados alcinilo como moduladores de receptores metabotrópicos de glutamato
WO2009075874A1 (en) Gamma secretase modulators
CN101291910A (zh) 钾通道抑制剂
JP2007535528A (ja) ヒスタミン−３受容体アンタゴニスト
KR102359707B1 (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
US5278162A (en) 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
KR20120101551A (ko) Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
KR101050910B1 (ko) 신규의 피리디닐아미노알킬렌 및 피리디닐옥시알킬렌 싸이클로프로판아민, 이의 제조 방법 및 이를 포함하는 약제학적 조성물
WO2015191681A2 (en) Substituted pyridinones as mgat2 inhibitors
JP2656157B2 (ja) 認識増強に有用な新規な神経伝達物質放出剤
SK124695A3 (en) Disubstituted polycyclic compounds and their derivatives alone and for treatment, and pharmaceutical compositions on their base
JP2650786B2 (ja) 認識力強化剤としてのジ置換多環式化合物
US4876259A (en) 3,3-disubstituted indolines
JP2009525335A (ja) カリウムチャネル阻害剤
KR102607510B1 (ko) 무스카린 m1 수용체 양성 알로스테릭 조절제로서의 피롤로-피리다진 유도체
NO179519B (no) Analogifremgangsmåte for fremstilling av 3-(1,2-benzisoksazol-3-yl)-4-pyridinaminer og derivater derav
RU2127732C1 (ru) Эфиры бис-фенилпиперазинникотиновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения расстройств центральной нервной системы
RU2344134C2 (ru) 1,1,2,2-тетра (гетеро) арилэтаны или 1,1,2-три (гетеро) арил-2-гетероциклилэтаны в качестве ингибиторов калиевых каналов
JP2017500318A (ja) 癌および炎症性疾患を処置するための新規化合物
KR102443402B1 (ko) 무스카린 m1 수용체 양성 알로스테릭 조절제로서 치환된 아자사이클
TW202400149A (zh) 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)